{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:33Z","timestamp":1790727393432,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Lenalidomide maintenance in myeloma is well established. Nevertheless, pomalidomide could provide an alternative. Myeloma patients in first relapse, initially treated in the Intergroupe Francophone du My\u00e9lome (IFM) 2009 trial, and subsequently in the IFM 2013\u201001 phase 2 trial, received four cycles of salvage therapy with pomalidomide plus cyclophosphamide plus dexamethasone (PCD) with transplantation plus 2 PCD consolidation or without transplantation but with 5 PCD and for all patients pomalidomide plus dexamethasone maintenance therapy. This consisted of 28\u2010day\u2009cycles of pomalidomide 4\u2009mg daily on days 1\u201321 and dexamethasone 20\u2009mg weekly until progression. The primary endpoint was an improved response to treatment. A total of 75\/100 patients reached therapy. The median follow\u2010up time was 73\u2009months. The median duration of treatment was 23.7\u2009months. One third of patients improved their response from the initiation of treatment: 11%, 19% and 4% to a very good partial response, complete response or stringent complete response respectively. The median progression\u2010free survival time was 33.2\u2009months and the median overall survival time was not reached. Among the 75 patients, the reasons for pomalidomide discontinuation were progressive disease (54%), adverse events (AEs) (30%), investigator discretion (11%) and consent withdrawal (5%). Grade (G) 3\/4 haematological AEs included neutropenia (51%) and lymphopenia (35%); G3\/4 drug\u2010related non\u2010haematological AEs (&gt;5%) comprised 13% infections. Long\u2010term administration of pomalidomide and dexamethasone is feasible and one third of the patients improved their response.<\/jats:p>","DOI":"10.1111\/bjh.18772","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T05:34:48Z","timestamp":1679981688000},"page":"1103-1115","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma"],"prefix":"10.1111","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-8112","authenticated-orcid":false,"given":"Laurent","family":"Garderet","sequence":"first","affiliation":[{"name":"INSERM, UMR_S 938, Proliferation and Differentiation of Stem Cells  Paris France"},{"name":"D\u00e9partement d'H\u00e9matologie AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re  Paris France"},{"name":"Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Kuhnowski","sequence":"additional","affiliation":[{"name":"Institut Curie  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Berge","sequence":"additional","affiliation":[{"name":"Euraxi  Jou\u00e9\u2010l\u00e8s\u2010Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Devlamynck","sequence":"additional","affiliation":[{"name":"D\u00e9partement Statistique Centre Hospitalier Universitaire  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Odile","family":"Petillon","sequence":"additional","affiliation":[{"name":"Maladies du Sang H\u00f4pital Claude Huriez, CHRU Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre\u2010Barbe","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lafon","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Maladies du Sang H\u00f4pital Claude Huriez, CHRU Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon  Pierre Benite Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie CHU de Toulouse IUCT Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Marie","family":"Stoppa","sequence":"additional","affiliation":[{"name":"Departement d'H\u00e9matologie Institut Paoli Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Immuno\u2010H\u00e9matologie H\u00f4pital Saint Louis  Paris France"},{"name":"Service d'H\u00e9matologie Clinique Centre Hospitalier Universitaire  Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Chaleteix","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Clermont Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tiab","sequence":"additional","affiliation":[{"name":"Hopital de La Roche sur Yon  La Roche sur Yon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Araujo","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de la C\u00f4te Basque  Bayonne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lenain","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-5434","authenticated-orcid":false,"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Henri Mondor  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souhila","family":"Ikhlef","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Hopital Saint Antoine  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve Avet","family":"Loiseau","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie CHU de Toulouse IUCT Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie CHU de Toulouse IUCT Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire H\u00f4tel Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-374249"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01631-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30366"},{"key":"e_1_2_8_11_1","first-page":"djv342","article-title":"Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta\u2010analysis and systematic review","volume":"108","author":"Wang Y","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0"},{"key":"e_1_2_8_14_1","unstructured":"Bristol Myers Squibb.REVLIMID (lenalidomide) capsules for oral use.2019Available from:https:\/\/packageinserts.bms.com\/pi\/pi_revlimid.pdf(accessed September 17 2020)"},{"key":"e_1_2_8_15_1","unstructured":"EMA.Revlimid (lenalidomide) summary of product characteristics.2020Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/revlimid\u2010epar\u2010productinformation_en.pdf(accessed September 17 2020)"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26361"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863829"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_23_1","unstructured":"Cancer Therapy Evaluation Program.Common terminology criteria for adverse events. Available from:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm(accessed March 1 2018)"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682518"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488676"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01021-3"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1941940"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02228"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134538"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612069"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T06:13:15Z","timestamp":1692425595000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/bjh.18772"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18772","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"2022-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}